I-MAB
0VY
Company Profile
Business description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,469.00 | 47.30 | 0.56% |
| CAC 40 | 7,694.44 | 67.60 | 0.89% |
| DAX 40 | 23,352.69 | 236.73 | 1.02% |
| Dow JONES (US) | 41,368.45 | 254.48 | 0.62% |
| FTSE 100 | 8,531.61 | 27.72 | -0.32% |
| HKSE | 22,845.27 | 69.35 | 0.30% |
| NASDAQ | 17,928.14 | 189.98 | 1.07% |
| Nikkei 225 | 37,495.74 | 567.11 | 1.54% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,663.94 | 32.66 | 0.58% |
| S&P/ASX 200 | 8,239.30 | 47.60 | 0.58% |
| SSE Composite Index | 3,345.12 | 6.88 | -0.21% |